Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2020-06-11 | 2020-06-11 |
| Drug Identification Number | 02443112 | 02443112 |
| Brand name | ACT OLMESARTAN HCT | ACT OLMESARTAN HCT |
| Common or Proper name | OLMESARTAN/HCTZ 20/12.5MG FC TAB | OLMESARTAN/HCTZ 20/12.5MG FC TAB |
| Company Name | TEVA CANADA LIMITED | TEVA CANADA LIMITED |
| Ingredients | OLMESARTAN MEDOXOMIL HYDROCHLOROTHIAZIDE | OLMESARTAN MEDOXOMIL HYDROCHLOROTHIAZIDE |
| Strength(s) | 20MG 12.5MG | 20MG 12.5MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 30's and 100's | 30's and 100's |
| ATC code | C09DA | C09DA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | ||
| Actual discontinuation date | 2020-06-08 | 2020-06-08 |
| Remaining supply date | 2020-06-08 | 2020-06-08 |
| Discontinuation status | Discontinued | Discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | ||
| Health Canada comments |